[ { "evidence_id": "EV-0101", "claim": "SURMOUNT-1 reported mean weight reductions of 16.0%, 21.4% and 22.5% at 72 weeks versus 2.4% with placebo", "source_title": "Tirzepatide Once Weekly for the Treatment of Obesity", "source_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2206038", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0101.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0102", "claim": "SURMOUNT-5 reported \u221220.2% weight change with tirzepatide versus \u221213.7% with semaglutide at 72 weeks", "source_title": "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity", "source_url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2416394", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0102.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0103", "claim": "SURMOUNT-OSA reported reductions in apnoea-hypopnoea index, weight, hypoxic burden, hsCRP and systolic blood pressure", "source_title": "Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity", "source_url": "https://www.nejm.org/doi/10.1056/NEJMoa2404881", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0103.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0104", "claim": "Three years of tirzepatide in obesity with prediabetes markedly lowered progression to type 2 diabetes versus placebo", "source_title": "Tirzepatide for Obesity Treatment and Diabetes Prevention", "source_url": "https://www.nejm.org/doi/abs/10.1056/NEJMoa2410819", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0104.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0105", "claim": "SURMOUNT-4 examined continued tirzepatide versus withdrawal for maintenance of weight reduction", "source_title": "Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial", "source_url": "https://jamanetwork.com/journals/jama/fullarticle/2812936", "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0105.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Registry identifier, sample size and numeric results not yet captured from the full text. Do not publish result figures until they are." }, { "evidence_id": "EV-0201", "claim": "FDA proposed on 30 April 2026 to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need", "source_title": "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List", "source_url": "https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list", "source_type": "Federal agency press announcement", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0201.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0202", "claim": "The formal notice appeared at 91 Fed. Reg. 23431 on 1 May 2026, docket 2026-08552", "source_title": "List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B", "source_url": "https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal", "source_type": "Federal Register notice", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0202.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0203", "claim": "FDA extended the comment period; comments must be submitted by 30 July 2026", "source_title": "Comment period extension, List of Bulk Drug Substances Under Section 503B", "source_url": "https://www.federalregister.gov/documents/full_text/html/2026/06/26/2026-12937.html", "source_type": "Federal Register notice", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0203.png", "strength": "Primary", "status": "verified", "next_review": "2026-07-31", "notes": "Live deadline. Re-check on 31 July 2026 and again when a final determination publishes." }, { "evidence_id": "EV-0301", "claim": "NexLife publishes tirzepatide (standard subcutaneous) at $215/month on the month-to-month plan, $215 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0301.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0302", "claim": "NexLife publishes tirzepatide (standard subcutaneous) at $195/month on the 3-month prepaid plan, $585 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0302.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0303", "claim": "NexLife publishes tirzepatide (standard subcutaneous) at $190/month on the 6-month prepaid plan, $1140 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0303.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0304", "claim": "NexLife publishes tirzepatide (standard subcutaneous) at $186/month on the 12-month prepaid plan, $2232 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0304.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0305", "claim": "NexLife publishes semaglutide (standard subcutaneous) at $165/month on the month-to-month plan, $165 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/semaglutide-all-plans", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0306", "claim": "NexLife publishes semaglutide (standard subcutaneous) at $149/month on the 3-month prepaid plan, $447 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/semaglutide-all-plans", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0307", "claim": "NexLife publishes semaglutide (standard subcutaneous) at $147/month on the 6-month prepaid plan, $882 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/semaglutide-all-plans", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0308", "claim": "NexLife publishes semaglutide (standard subcutaneous) at $145/month on the 12-month prepaid plan, $1740 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide standard subcutaneous plans", "source_url": "https://nexlife.us/pages/semaglutide-all-plans", "source_type": "Provider's own published plan page", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0308.png", "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-24", "notes": null }, { "evidence_id": "EV-0309", "claim": "NexLife publishes tirzepatide (microdose) at $189/month on the month-to-month plan, $189 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide microdose plans", "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0310", "claim": "NexLife publishes tirzepatide (microdose) at $159/month on the 3-month prepaid plan, $479 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide microdose plans", "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0311", "claim": "NexLife publishes tirzepatide (microdose) at $150/month on the 6-month prepaid plan, $899 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide microdose plans", "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0312", "claim": "NexLife publishes tirzepatide (microdose) at $147/month on the 12-month prepaid plan, $1764 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide microdose plans", "source_url": "https://nexlife.us/pages/microdose-tirzepatide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0313", "claim": "NexLife publishes semaglutide (microdose) at $129/month on the month-to-month plan, $129 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide microdose plans", "source_url": "https://nexlife.us/pages/microdose-semaglutide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0314", "claim": "NexLife publishes semaglutide (microdose) at $117/month on the 3-month prepaid plan, $357 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide microdose plans", "source_url": "https://nexlife.us/pages/microdose-semaglutide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0315", "claim": "NexLife publishes semaglutide (microdose) at $114/month on the 6-month prepaid plan, $684 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide microdose plans", "source_url": "https://nexlife.us/pages/microdose-semaglutide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0316", "claim": "NexLife publishes semaglutide (microdose) at $110/month on the 12-month prepaid plan, $1320 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide microdose plans", "source_url": "https://nexlife.us/pages/microdose-semaglutide-program", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0317", "claim": "NexLife publishes tirzepatide (sublingual ODT) at $229/month on the month-to-month plan, $229 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-tirzepatide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0318", "claim": "NexLife publishes tirzepatide (sublingual ODT) at $219/month on the 3-month prepaid plan, $657 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-tirzepatide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0319", "claim": "NexLife publishes tirzepatide (sublingual ODT) at $205/month on the 6-month prepaid plan, $1230 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-tirzepatide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0320", "claim": "NexLife publishes tirzepatide (sublingual ODT) at $199/month on the 12-month prepaid plan, $2388 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Tirzepatide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-tirzepatide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0321", "claim": "NexLife publishes semaglutide (sublingual ODT) at $199/month on the month-to-month plan, $199 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-semaglutide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0322", "claim": "NexLife publishes semaglutide (sublingual ODT) at $185/month on the 3-month prepaid plan, $597 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-semaglutide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0323", "claim": "NexLife publishes semaglutide (sublingual ODT) at $177/month on the 6-month prepaid plan, $1062 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-semaglutide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0324", "claim": "NexLife publishes semaglutide (sublingual ODT) at $165/month on the 12-month prepaid plan, $1980 total, with no membership fee, free shipping and flat pricing across eligible doses", "source_title": "NexLife \u2014 Semaglutide sublingual ODT plans", "source_url": "https://nexlife.us/pages/sublingual-semaglutide-odt", "source_type": "Provider's own published plan page", "capture_date": null, "reviewer": null, "archive": null, "strength": "Provider-supplied, unconfirmed", "status": "reported", "next_review": "2026-08-24", "notes": "Figure supplied to the editorial desk. Confirm against the live plan page and archive a screenshot before this row may be described as verified or used in any comparative claim." }, { "evidence_id": "EV-0350", "claim": "NexLife states it is LegitScript-certified", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Verify directly in the LegitScript certification lookup, not on the provider's own page." }, { "evidence_id": "EV-0351", "claim": "NexLife states it works exclusively with LegitScript-certified, NABP-accredited pharmacies", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Name the specific pharmacy or pharmacies and verify each accreditation with the accrediting body." }, { "evidence_id": "EV-0352", "claim": "NexLife states every batch undergoes independent third-party testing for potency, sterility, pH and endotoxin", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Ask who performs the testing, whether a certificate of analysis is available to patients, and for a sample COA." }, { "evidence_id": "EV-0353", "claim": "NexLife states compounded medication is prepared by U.S.-licensed 503A compounding pharmacies", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "One NexLife page references 503A; third-party coverage references both 503A and 503B. Resolve which applies, because the regulatory position and the pending FDA 503B bulks proposal differ materially between them." }, { "evidence_id": "EV-0354", "claim": "NexLife states availability in all 50 states", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Verify state by state against checkout or written support confirmation. A national marketing claim is not evidence of availability in any specific state." }, { "evidence_id": "EV-0355", "claim": "NexLife cites SURMOUNT-1 as showing average weight loss of up to 24.3% over 72 weeks", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "The SURMOUNT-1 efficacy-estimand results published in NEJM were 16.0%, 21.4% and 22.5% at 5, 10 and 15 mg. Establish which analysis the 24.3% figure comes from before repeating it. Separately, SURMOUNT-1 studied the FDA-approved product, not a compounded preparation, so the result does not transfer automatically." }, { "evidence_id": "EV-0356", "claim": "NexLife references self-reported outcomes from 518 members", "source_title": "NexLife published website content", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider claim", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Provider-reported", "status": "reported", "next_review": "2026-08-24", "notes": "Self-reported member data is not trial evidence. If cited at all, label it as self-reported, state the denominator and response rate, and never present it beside trial figures without that distinction." }, { "evidence_id": "EV-0106", "claim": "SUMMIT reported a 38% reduction in the combined endpoint of death and worsening heart-failure events in obesity-related HFpEF", "source_title": "Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy", "source_url": "https://www.jacc.org/doi/10.1016/j.jacc.2024.11.001", "source_type": "Peer-reviewed substudy of a randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": "archives/EV-0106.png", "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Capture the primary SUMMIT publication DOI and the absolute event rates before publishing the relative risk reduction alone." }, { "evidence_id": "EV-0107", "claim": "Retatrutide phase 3 figures circulating in commercial secondary sources are unconfirmed against a primary publication", "source_title": "Retatrutide phase 2 trial", "source_url": "https://doi.org/10.1056/NEJMoa2301972", "source_type": "Peer-reviewed randomised controlled trial (phase 2)", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary for phase 2 only", "status": "reported", "next_review": "2026-08-24", "notes": "Several sites publishing phase 3 retatrutide figures are peptide vendors or carry provider advertising inside clinical copy. Treat as unverified." }, { "evidence_id": "EV-04001", "claim": "Found lists tirzepatide (compounded injectable) at $169 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04002", "claim": "NexLife lists tirzepatide (compounded injectable) at $186 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Standard injection, 12-month plan ($2,232). 6-month $190; 3-month $195; month-to-month $215. No membership fee, flat at every covered dose.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04003", "claim": "Oak Longevity lists tirzepatide (compounded injectable) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04004", "claim": "Shed lists tirzepatide (compounded injectable) at $245 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04005", "claim": "Mochi Health lists tirzepatide (compounded injectable) at $278 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04006", "claim": "Enhance.MD lists tirzepatide (compounded injectable) at $280 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04007", "claim": "Eden lists tirzepatide (compounded injectable) at $298 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04008", "claim": "Noom Med lists tirzepatide (compounded injectable) at $299 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04009", "claim": "TrimRx lists tirzepatide (compounded injectable) at $349 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04010", "claim": "MEDVi lists tirzepatide (compounded injectable) at $399 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": null, "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "pending", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04011", "claim": "bmiMD lists tirzepatide (compounded injectable) at $399 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04012", "claim": "NexLife lists tirzepatide (compounded microdose) at $147 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Microdose, 12-month plan ($1,764). Month-to-month $189; 6-month $150; 3-month $160. Below every dose studied in the trials.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04013", "claim": "Enhance.MD lists tirzepatide (compounded microdose) at $169 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04014", "claim": "Shed lists tirzepatide (compounded microdose) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04015", "claim": "bmiMD lists tirzepatide (compounded microdose) at $349 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04016", "claim": "NexLife lists tirzepatide (compounded oral / ODT) at $199 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "ODT, 12-month plan ($2,388). Month-to-month $229; 6-month $205; 3-month $219. No trial has tested this dosage form.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04017", "claim": "Henry Meds lists tirzepatide (compounded oral / ODT) at $349 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04018", "claim": "NexLife lists semaglutide (compounded microdose) at $110 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Microdose, 12-month plan ($1,320). Month-to-month $129; 6-month $114; 3-month $119. Below every dose studied in the trials.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04019", "claim": "Shed lists semaglutide (compounded microdose) at $149 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04020", "claim": "Oak Longevity lists semaglutide (compounded injectable) at $133 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04021", "claim": "NexLife lists semaglutide (compounded injectable) at $145 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Standard injection, 12-month plan ($1,740). Month-to-month $165; 6-month $147; 3-month $149. No membership fee, flat at every covered dose.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04022", "claim": "Found lists semaglutide (compounded injectable) at $169 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04023", "claim": "Shed lists semaglutide (compounded injectable) at $175 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04024", "claim": "Mochi Health lists semaglutide (compounded injectable) at $178 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04025", "claim": "Eden lists semaglutide (compounded injectable) at $198 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04026", "claim": "Noom Med lists semaglutide (compounded injectable) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04027", "claim": "TrimRx lists semaglutide (compounded injectable) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04028", "claim": "Enhance.MD lists semaglutide (compounded injectable) at $212 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04029", "claim": "bmiMD lists semaglutide (compounded injectable) at $289 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04030", "claim": "Henry Meds lists semaglutide (compounded injectable) at $297 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04031", "claim": "MEDVi lists semaglutide (compounded injectable) at $299 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04032", "claim": "NexLife lists semaglutide (compounded oral / ODT) at $165 per month, total including any required membership", "source_title": "NexLife published self-pay programme pages", "source_url": null, "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "ODT, 12-month plan ($1,980). Month-to-month $199; 6-month $177; 3-month $185. No trial has tested this dosage form.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04033", "claim": "Henry Meds lists semaglutide (compounded sublingual) at $179 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04034", "claim": "Shed lists semaglutide (compounded sublingual) at $199 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04035", "claim": "Shed lists semaglutide (compounded sublingual) at $229 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04036", "claim": "Henry Meds lists semaglutide (compounded oral / ODT) at $249 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04037", "claim": "MEDVi lists semaglutide (compounded oral / ODT) at $369 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": null, "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "pending", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04038", "claim": "Found lists liraglutide (compounded injectable) at $169 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04039", "claim": "Henry Meds lists liraglutide (compounded injectable) at $179 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04040", "claim": "LillyDirect lists orforglipron (Foundayo) (brand oral, FDA-approved) at $149 per month, total including any required membership", "source_title": "Manufacturer self-pay pricing page", "source_url": null, "capture_date": "2026-07-06", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "0.8 mg starter, Self Pay Journey Program. Rises to $199 (2.5 mg), $299 (5.5/9 mg), $349 (14.5/17.2 mg); drops to $299 on refill within 45 days.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04041", "claim": "NovoCare Pharmacy lists semaglutide (Wegovy tablets) (brand oral, FDA-approved) at $149 per month, total including any required membership", "source_title": "Manufacturer self-pay pricing page", "source_url": null, "capture_date": "2026-07-06", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Wegovy tablets, 1.5 mg and 4 mg.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04042", "claim": "LillyDirect lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $299 per month, total including any required membership", "source_title": "Manufacturer self-pay pricing page", "source_url": null, "capture_date": "2026-07-06", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "2.5 mg starter vial, Self Pay Journey Program. 5 mg $399; 7.5\u201315 mg $449, requiring refill within 45 days to hold the rate.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04043", "claim": "NovoCare Pharmacy lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $349 per month, total including any required membership", "source_title": "Manufacturer self-pay pricing page", "source_url": null, "capture_date": "2026-07-06", "reviewer": "Editorial research desk", "source_type": "Provider's own published page", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-06", "notes": "Month three onward, all maintenance doses. Reduced from $499 in November 2025.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-04044", "claim": "PlushCare lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $319 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04045", "claim": "WeightWatchers Clinic lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $323 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04046", "claim": "Hims lists semaglutide (Wegovy tablets) (brand oral, FDA-approved) at $298 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04047", "claim": "Ro lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $348 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04048", "claim": "Found lists tirzepatide (Zepbound) (brand injectable, FDA-approved) at $447 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04049", "claim": "Eden lists semaglutide (Wegovy) (brand injectable, FDA-approved) at $1794 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-04050", "claim": "Hers lists tirzepatide (Mounjaro) (brand injectable, FDA-approved) at $2048 per month, total including any required membership", "source_title": "Provider pricing dataset, July 2026", "source_url": null, "capture_date": "2026-07-06", "reviewer": null, "source_type": "Third-party dataset", "archive": null, "strength": "Secondary, third-party reported", "status": "reported", "next_review": "2026-08-06", "notes": "Third-party reported figure. Not captured by us. Under our own labelling rule this cannot be described as verified, and cannot support a comparative claim, until a researcher opens the provider's page and archives it." }, { "evidence_id": "EV-0108", "claim": "SURMOUNT-3 reported \u221218.4% additional weight reduction after a lifestyle lead-in versus +2.5% placebo", "source_title": "Wadden TA et al., Nature Medicine 2023", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0109", "claim": "SURMOUNT-4 reported 5.5% further loss on continued treatment against 14.0% regain after withdrawal", "source_title": "Aronne LJ et al., JAMA 2024", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0110", "claim": "SURPASS-2 reported HbA1c reductions of 2.01\u20132.30% with tirzepatide versus 1.86% with semaglutide 1 mg", "source_title": "Fr\u00edas JP et al., N Engl J Med 2021", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0111", "claim": "SURPASS-CVOT found tirzepatide non-inferior to dulaglutide for major adverse cardiovascular events", "source_title": "SURPASS-CVOT, 2024", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0112", "claim": "SURMOUNT-1 publishes two estimands; the treatment-regimen figures are 15.0/19.5/20.9% and the efficacy figures are 16.0/21.4/22.5%", "source_title": "Jastreboff AM et al., N Engl J Med 2022", "source_url": null, "source_type": "Peer-reviewed randomised controlled trial", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve and archive the full text; record DOI and PMID.", "demoted_reason": "Marked verified without a capture date, source URL and named reviewer" }, { "evidence_id": "EV-0501", "claim": "The Federation of State Medical Boards maintains a public directory of every state medical board", "source_title": "FSMB \u2014 Contact a State Medical Board", "source_url": "https://www.fsmb.org/contact-a-state-medical-board/", "source_type": "National regulatory federation directory", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "FSMB represents 70 state medical and osteopathic boards across the US, its territories and DC." }, { "evidence_id": "EV-0502", "claim": "The National Association of Boards of Pharmacy maintains a public directory of state boards of pharmacy", "source_title": "NABP \u2014 Contact Your Board", "source_url": "https://nabp.pharmacy/about/boards-of-pharmacy/", "source_type": "National regulatory association directory", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Active member boards cover all 50 states, DC, Guam, Puerto Rico and the Virgin Islands." }, { "evidence_id": "EV-0113", "claim": "Orforglipron (Foundayo) was FDA-approved on 1 April 2026 for chronic weight management, with reported mean weight reduction of approximately 11% to 12.4% at the highest dose over 72 weeks", "source_title": "FDA approves Lilly's Foundayo (orforglipron)", "source_url": "https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill", "source_type": "Manufacturer announcement", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Manufacturer announcement. The efficacy figure varies between 11% and 12.4% across sources without a consistently stated estimand. Capture the ATTAIN-1 publication before charting a single number." }, { "evidence_id": "EV-0114", "claim": "OASIS 4 reported 13.6% mean weight reduction on the treatment-policy estimand and 16.6% among adherent participants, against 2.2% and 2.7% with placebo", "source_title": "Wharton S et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. N Engl J Med 2025;393(11):1077-1087", "source_url": "https://doi.org/10.1056/NEJMoa2500969", "source_type": "Trade press", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0115", "claim": "The Wegovy pill (oral semaglutide 25 mg) was FDA-approved on 22 December 2025 for weight management and for reducing the risk of major adverse cardiovascular events", "source_title": "Novo Nordisk: Wegovy pill approved in the US as first oral GLP-1 for weight management", "source_url": "https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472", "source_type": "Manufacturer announcement", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0116", "claim": "LillyDirect self-pay pricing for Foundayo runs $149 to $349 by dose, with $299 on the top two doses when timely refill requirements are met; $25 per month with an eligible commercial savings card and $50 for eligible Medicare Part D patients from 1 July 2026", "source_title": "FDA Approves Lilly's Oral GLP-1 Orforglipron for Obesity", "source_url": "https://www.ajmc.com/view/fda-approves-lilly-s-oral-glp-1-orforglipron-for-obesity", "source_type": "Manufacturer announcement", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Trade press reporting of manufacturer pricing. Re-capture from LillyDirect's own page before describing as verified." }, { "evidence_id": "EV-0601", "claim": "FDA states that registration as an outsourcing facility means only that the agency has received the required information. It does not mean the facility is making FDA-approved drugs, and it does not mean the facility is in compliance with CGMP requirements or the other conditions of section 503B", "source_title": "Questions and Answers: Outsourcing Facility Registration", "source_url": "https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration", "source_type": "Federal agency guidance", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "This is the agency's own wording and it is stronger than the common summary. CGMP compliance is a legal requirement under 503B; registration is not evidence that a given facility meets it." }, { "evidence_id": "EV-0602", "claim": "FDA maintains a public register of outsourcing facilities and a searchable Outsourcing Facility Product Report database covering the last four reporting periods", "source_title": "Information for Outsourcing Facilities", "source_url": "https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities", "source_type": "Federal agency register", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "A facility is removed from the list when it is no longer registered. Check currency, not merely presence." }, { "evidence_id": "EV-0603", "claim": "Section 503B was created by the Drug Quality and Security Act, signed into law on 27 November 2013", "source_title": "Information for Outsourcing Facilities \u2014 Drug Quality and Security Act", "source_url": "https://www.fda.gov/drugs/human-drug-compounding/information-outsourcing-facilities", "source_type": "Federal agency guidance", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0604", "claim": "FDA's registration guidance for outsourcing facilities is issued under docket FDA-2013-N-1429", "source_title": "Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B", "source_url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/registration-human-drug-compounding-outsourcing-facilities-under-section-503b-federal-food-drug-and", "source_type": "Federal agency guidance", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0605", "claim": "FDA's 2019 guidance interpreting clinical need for the 503B bulks list states that clinical need is distinct from supply constraints or cost considerations", "source_title": "FDA Proposes to Exclude GLP-1 Receptor Agonists from the 503B Bulks List \u2014 analysis", "source_url": "https://www.frierlevitt.com/articles/fda-glp1-503b-bulks-list-proposed-exclusion-semaglutide-tirzepatide-liraglutide/", "source_type": "Legal analysis of federal guidance", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Retrieve FDA's 2019 clinical-need guidance directly and cite the agency document rather than this analysis before relying on the wording." }, { "evidence_id": "EV-0606", "claim": "PCAB accreditation is administered through ACHC", "source_title": "503A vs 503B compounding pharmacy \u2014 industry reference", "source_url": "https://tccompound.com/blogs/health-hub/503a-vs-503b", "source_type": "Industry source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Confirm directly with ACHC and capture the public accreditation lookup before describing any provider's PCAB claim as verified." }, { "evidence_id": "EV-0607", "claim": "Reporting indicates FDA issued warning letters to approximately 30 telehealth firms over claims that compounded GLP-1s are identical to branded drugs, with 50 or more warning letters to compounders and distributors during 2025", "source_title": "FDA Proposes to Exclude GLP-1s From 503B Bulk List", "source_url": "https://www.drugtopics.com/view/fda-proposes-to-exclude-glp-1s-from-503b-bulk-list", "source_type": "Trade press", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Counts come from trade press. Verify against FDA's own warning letter database before publishing a number." }, { "evidence_id": "EV-0608", "claim": "Novo Nordisk litigation has alleged that some compounded semaglutide contained impurities at levels up to 86%", "source_title": "FDA Proposes to Exclude GLP-1s From 503B Bulk List", "source_url": "https://www.drugtopics.com/view/fda-proposes-to-exclude-glp-1s-from-503b-bulk-list", "source_type": "Trade press reporting a litigation allegation", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "This is an allegation in litigation by a competitor manufacturer, not an established finding. Do not publish as fact. If used at all, attribute to the litigation and note it is contested." }, { "evidence_id": "EV-0701", "claim": "The Zepbound label directs starting at 2.5 mg once weekly for 4 weeks, increasing to 5 mg, then increasing in 2.5 mg increments no sooner than every 4 weeks, to a maximum of 15 mg once weekly", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "The label sets a minimum interval, not a fixed calendar. Escalation is based on tolerability and response." }, { "evidence_id": "EV-0702", "claim": "The label states the 2.5 mg dosage is for treatment initiation and is not approved as a maintenance dosage", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "This is the label's own wording. It is the strongest available support for the point that an advertised price quoted at 2.5 mg is not the price of treatment." }, { "evidence_id": "EV-0703", "claim": "The recommended maintenance dosages are 5 mg, 10 mg or 15 mg once weekly. 7.5 mg and 12.5 mg are titration steps, not recommended maintenance dosages", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Correcting an earlier version of our titration table, which presented all six strengths as a sequential schedule." }, { "evidence_id": "EV-0704", "claim": "Zepbound carries a boxed warning for thyroid C-cell tumours observed in rats. Human relevance has not been determined. It is contraindicated in personal or family history of medullary thyroid carcinoma, in Multiple Endocrine Neoplasia syndrome type 2, and in known serious hypersensitivity to tirzepatide or its excipients", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Anaphylaxis and angioedema have been reported. Routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early MTC detection, per the label." }, { "evidence_id": "EV-0705", "claim": "The label states that coadministration with other tirzepatide-containing products, or with any GLP-1 receptor agonist, is not recommended", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "Directly relevant to this market: a patient using a compounded preparation alongside a branded product, or alongside another GLP-1, is doing something the label advises against." }, { "evidence_id": "EV-0706", "claim": "Zepbound is indicated both for chronic weight management and for moderate-to-severe obstructive sleep apnoea in adults with obesity", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": "The OSA indication followed the SURMOUNT-OSA programme." }, { "evidence_id": "EV-0707", "claim": "Zepbound is supplied at 2.5, 5, 7.5, 10, 12.5 and 15 mg per 0.5 mL, administered once weekly at any time of day with or without meals, into the abdomen, thigh or upper arm with site rotation", "source_title": "ZEPBOUND (tirzepatide) US Prescribing Information", "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s003lbl.pdf", "source_type": "FDA-approved product labelling", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0708", "claim": "In SURMOUNT-1, discontinuation due to an adverse event ranged from 4.3% to 7.1% across tirzepatide doses against 2.6% with placebo, and 50% and 57% of the 10 mg and 15 mg groups achieved 20% or greater weight reduction against 3% with placebo", "source_title": "Tirzepatide prescribing guide", "source_url": "https://www.medcentral.com/drugs/guide/tirzepatide", "source_type": "Clinical reference", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary clinical reference. Confirm the discontinuation range and the 20% responder rates against the NEJM publication before relying on them." }, { "evidence_id": "EV-0801", "claim": "FDA issued 25 warning letters on 16 June 2026 to telehealth companies alleging false or misleading website claims about compounded semaglutide, tirzepatide and, in one case, liraglutide", "source_title": "FDA takes aim at misleading online claims for compounded GLP-1 drugs", "source_url": "https://www.lexology.com/library/detail.aspx?g=b1701277-892b-43a9-90cd-529b7263e16e", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0802", "claim": "FDA issued more than 55 warning letters on 16 September 2025 to online sellers of compounded GLP-1s citing misleading direct-to-consumer advertising", "source_title": "FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown", "source_url": "https://www.pharmacytimes.com/view/fda-and-novo-nordisk-warned-of-glp-1-telehealth-compounding-take-down-what-s-next-", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0803", "claim": "FDA issued 30 warning letters to telehealth companies in early 2026 threatening legal action without further notice; Commissioner Makary described it as a new era of enforcement", "source_title": "FDA ramps up crackdown on GLP-1 drug compounding with fresh batch of 30 warning letters", "source_url": "https://www.fiercepharma.com/pharma/fda-ramps-crackdown-glp-1-drug-compounders-fresh-batch-30-warning-letters", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0804", "claim": "On 6 February 2026 FDA announced it would take steps to restrict GLP-1 active pharmaceutical ingredients used in non-FDA-approved compounded products", "source_title": "FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs", "source_url": "https://www.pharmacytimes.com/view/fda-and-novo-nordisk-warned-of-glp-1-telehealth-compounding-take-down-what-s-next-", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0805", "claim": "The FDA drug shortage record shows tirzepatide injection determined resolved on 2 October 2024; on 22 October 2024 that decision was remanded to the agency for reevaluation as part of litigation, and on 5 March 2025 a district court denied the plaintiffs' preliminary injunction in Outsourcing Facilities Association v. FDA", "source_title": "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize", "source_url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize", "source_type": "Federal agency record", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0806", "claim": "FDA set 22 May 2025 as the date until which it did not intend to take action against outsourcing facilities for violations depending on semaglutide injection's inclusion on the shortage list", "source_title": "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize", "source_url": "https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize", "source_type": "Federal agency record", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0807", "claim": "As of early 2025 FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide, many involving dosing errors from multidose vials, some requiring hospitalisation", "source_title": "FDA Moves to Permanently Close the Door on Compounded GLP-1s", "source_url": "https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0808", "claim": "A 2026 study found that when tirzepatide is compounded with vitamin B12 the two substances can chemically bond, forming a molecule not present in the FDA-approved product. Compounders commonly add B12, B6, niacinamide, glycine or carnitine, combinations largely untested in clinical trials", "source_title": "Compounded GLP-1s: Why doctors worry and the FDA is cracking down", "source_url": "https://med.stanford.edu/news/insights/2026/07/glp1s-compounded-why-doctors-worry-about-safety.html", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0809", "claim": "TrumpRx launched on 5 February 2026 advertising direct access to lower-cost FDA-approved GLP-1s, listing semaglutide tablets at $149 to $299, semaglutide injections at $199 to $349 and tirzepatide injections at $299 to $449", "source_title": "FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown", "source_url": "https://www.pharmacytimes.com/view/fda-and-novo-nordisk-warned-of-glp-1-telehealth-compounding-take-down-what-s-next-", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0810", "claim": "The FDA Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 to review BPC-157, TB-500 and five other peptides for the 503A compounding list; briefing documents posted 30 June 2026 recommended against adding them", "source_title": "GLP-1 and peptide news digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0811", "claim": "Sandoz and Amneal filed abbreviated new drug applications for generic tirzepatide in 2026; Eli Lilly patents are reported to run to 2036", "source_title": "Generic Tirzepatide: FDA Review and Patent Timeline", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0812", "claim": "STEP UP reported semaglutide 7.2 mg producing 20.7% weight loss, narrowing the gap with tirzepatide", "source_title": "STEP UP trial digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0813", "claim": "REIMAGINE 2 reported CagriSema reducing HbA1c 1.91 points more than semaglutide alone with 14.2% weight loss in 2,728 adults with type 2 diabetes", "source_title": "REIMAGINE 2 digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0814", "claim": "SOUL reported oral semaglutide reducing major adverse cardiovascular events by 14% and heart failure events by 22% in 9,647 high-risk patients with type 2 diabetes", "source_title": "SOUL trial digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0815", "claim": "EVOKE and EVOKE+ enrolled 3,808 participants over two years and found oral semaglutide made no difference to Alzheimer's disease progression", "source_title": "EVOKE trials digest", "source_url": "https://www.compoundprotocol.com/news", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0816", "claim": "Novo Nordisk reported the Wegovy pill surpassing three million prescriptions in just over five months from its January 2026 launch", "source_title": "FDA approves Novo Nordisk's Wegovy pill", "source_url": "https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html", "source_type": "Trade press or secondary source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Secondary source. Verify against the primary document before relying on figures." }, { "evidence_id": "EV-0901", "claim": "The Interstate Medical Licensure Compact affirms that the practice of medicine occurs where the patient is located at the time of the physician-patient encounter, and that a physician licensed via the compact is under the jurisdiction of the medical board in the state where the patient is located", "source_title": "Interstate Medical Licensure Compact states list and guide", "source_url": "https://comphealth.com/resources/interstate-medical-licensure-compact", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "This is the governing principle for telehealth prescribing. Verify against the IMLC's own materials before describing as verified." }, { "evidence_id": "EV-0902", "claim": "The IMLC is an expedited pathway to obtaining multiple separate state licences, not a single multistate licence. Each state continues to issue, renew and regulate its own licence", "source_title": "Telehealth Licensure 2025-2026: Cross-State Practice", "source_url": "https://telehealth.org/news/telehealth-licensure-2025-2026-cross-state-practice-and-compacts/", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-0903", "claim": "The IMLC reports 44 member states plus the District of Columbia and Guam as of 2026, with participation levels differing between members", "source_title": "IMLC providing expedited licensure in 44 states in 2026", "source_url": "https://weatherbyhealthcare.com/blog/interstate-medical-licensure-compact", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Membership changes. Re-check against the IMLC's own list before relying on it." }, { "evidence_id": "EV-0904", "claim": "The Nurse Licensure Compact is a multistate licence, distinct from the IMLC. Source counts differ: one lists 41 member states as of June 2026, another 43 jurisdictions in the enhanced compact as of April 2026", "source_title": "Nurse Licensure Compact member states", "source_url": "https://en.wikipedia.org/wiki/Nurse_Licensure_Compact", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Two reputable sources give different counts. Both are recorded; neither is presented as settled." }, { "evidence_id": "EV-0905", "claim": "Advanced Practice Registered Nurses are covered by the APRN Compact and physician assistants by the PA Licensure Compact, which are separate from the IMLC", "source_title": "Interstate Medical Licensure Compact: What It Means for You", "source_url": "https://practiceseeker.com/resources/interstate-medical-licensure-compact-what-it-means-for-you", "source_type": "Industry or reference source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-1001", "claim": "SYNERGY-NASH was a phase 2 dose-finding trial of tirzepatide in adults with biopsy-confirmed MASH and stage F2-F3 fibrosis, published as Loomba R et al., N Engl J Med 2024;391(4):299-310, registry NCT04166773", "source_title": "Study Details NCT04166773 \u2014 ClinicalTrials.gov", "source_url": "https://clinicaltrials.gov/study/NCT04166773", "source_type": "Trial registry", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-1002", "claim": "Secondary sources report materially different MASH resolution rates for the 15 mg arm of SYNERGY-NASH: one gives 73.3% against 13.2% placebo, another 62% against 10% placebo", "source_title": "Conflicting secondary coverage of SYNERGY-NASH", "source_url": "https://www.appliedclinicaltrialsonline.com/view/tirzepatide-shows-efficacy-resolving-metabolic-dysfunction-associated-steatohepatitis-without-worsening-of-fibrosis", "source_type": "Trade press or commercial source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Do not publish a single resolution figure until the NEJM full text is read. The discrepancy is the reason." }, { "evidence_id": "EV-1003", "claim": "Tirzepatide is under evaluation for chronic kidney disease and has no completed dedicated kidney outcomes trial. Semaglutide's kidney outcomes evidence comes from the FLOW trial", "source_title": "Tirzepatide Shows Efficacy Resolving MASH \u2014 indications under evaluation", "source_url": "https://www.appliedclinicaltrialsonline.com/view/tirzepatide-shows-efficacy-resolving-metabolic-dysfunction-associated-steatohepatitis-without-worsening-of-fibrosis", "source_type": "Trade press or commercial source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": null }, { "evidence_id": "EV-1004", "claim": "A phase 3 programme, SYNERGY-OUTCOMES, launched in late 2025 with completion targeted for 2032", "source_title": "GLP-1s and fatty liver disease \u2014 pipeline summary", "source_url": "https://thepeptidecatalog.com/articles/glp1-fatty-liver-mash-fda-approved", "source_type": "Trade press or commercial source", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-10-24", "notes": "Source is a commercial peptide site and also asserts tirzepatide is FDA-approved for MASH, which conflicts with trade coverage describing it as under evaluation. Treat all claims from this source as unverified." }, { "evidence_id": "EV-1101", "claim": "NexLife states that it serves patients nationwide across all 50 states", "source_title": "NexLife \u2014 tirzepatide plans", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published page", "capture_date": "2026-07-11", "reviewer": "Editorial research desk", "archive": "archives/nexlife-plans-2026-07-11.png", "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-11", "notes": "This is NexLife's own stated position, captured from its published page. We report it as the provider's claim. Confirming it for a given state additionally requires prescriber licensure, pharmacy dispensing authority and current intake eligibility in that state, which we have not checked." }, { "evidence_id": "EV-1201", "claim": "Reporting states Embody keeps its entry price low \u2014 tirzepatide injections start at $149 for the first month \u2014 but refills then move to standard ongoing pricing of $399 per month, so it is not a flat-rate programme", "source_title": "Best Compounded Tirzepatide Providers (2026)", "source_url": "https://weightlossproviderguide.com/best-compounded-tirzepatide", "source_type": "Third-party comparison publication", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-24", "notes": "Competitor pricing reported by a third party. We have not captured it from the provider's own page. Figures for the same provider differ materially between sources, which is itself the finding." }, { "evidence_id": "EV-1202", "claim": "Embody's advertised tirzepatide starting rate has been reported at $99, $119, $129 and $149 across sources published within roughly two months, described in one as a promotional Summer Start rate that rises with dose and plan length", "source_title": "Embody GLP-1 Tirzepatide Review 2026", "source_url": "https://www.glp1clinics.org/blog/embody-review", "source_type": "Third-party comparison publication", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-24", "notes": "Competitor pricing reported by a third party. We have not captured it from the provider's own page. Figures for the same provider differ materially between sources, which is itself the finding." }, { "evidence_id": "EV-1203", "claim": "Yucca Health's $146 monthly figure is its compounded semaglutide rate; its compounded tirzepatide is reported at $258 per month on a six-month commitment", "source_title": "Cheapest Tirzepatide in 2026", "source_url": "https://www.peptidedeck.com/peptides/cheapest-tirzepatide", "source_type": "Third-party comparison publication", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-24", "notes": "Competitor pricing reported by a third party. We have not captured it from the provider's own page. Figures for the same provider differ materially between sources, which is itself the finding." }, { "evidence_id": "EV-1204", "claim": "TrimRx compounded tirzepatide is reported at $349 per month with flat pricing as the dose escalates; a separate source reports $449 per month standard with a $279 first-month rate on some monthly plans", "source_title": "How Much Does TrimRx Cost? Complete 2026 Pricing Guide", "source_url": "https://yourhealthmagazine.net/article/consumer-health-guides/how-much-does-trimrx-cost-complete-2026-pricing-guide/", "source_type": "Third-party comparison publication", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-24", "notes": "Competitor pricing reported by a third party. We have not captured it from the provider's own page. Figures for the same provider differ materially between sources, which is itself the finding." }, { "evidence_id": "EV-1205", "claim": "Compounded tirzepatide pricing is reported to range from $99 per month at starter doses to over $300 at full therapeutic doses depending on the provider's dose-tiering model, and many dose-tiered providers charge their highest prices at the 10 mg and 15 mg doses where SURMOUNT-1 showed the largest reductions", "source_title": "Cheapest Tirzepatide Providers 2026", "source_url": "https://trytrimi.com/blog/cheapest-tirzepatide-providers-ranked-2026", "source_type": "Third-party comparison publication", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-24", "notes": "Competitor pricing reported by a third party. We have not captured it from the provider's own page. Figures for the same provider differ materially between sources, which is itself the finding." }, { "evidence_id": "EV-1206", "claim": "Reported dose-escalation behaviour: SkinnyRx rises from $129 toward $299 at higher tirzepatide doses; ShedRx from $199 toward $299; MEDVi from $179 to $299 after month one", "source_title": "Cheapest Compounded Tirzepatide Online: 6 Verified Programs Compared", "source_url": "https://www.glp1watchdog.com/blog/cheapest-compounded-tirzepatide", "source_type": "Third-party comparison publication", "capture_date": "2026-07-24", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-24", "notes": "Competitor pricing reported by a third party. We have not captured it from the provider's own page. Figures for the same provider differ materially between sources, which is itself the finding." }, { "evidence_id": "EV-1301", "claim": "On 23 July 2026 the FDA Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend BPC-157, KPV and TB-500 for the 503A bulks list, and 7-5 with two abstentions for MOTS-c, overriding FDA staff reviewers who had recommended against all seven substances under review", "source_title": "FDA advisory committee backs two controversial peptides", "source_url": "https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1302", "claim": "The committee's votes are non-binding. FDA makes the final determination through formal notice-and-comment rulemaking, and three distinct legal events are routinely conflated: removal from Category 2, a PCAC recommendation, and actual placement on the Category 1 compoundable list, which commonly requires 8 to 12 months", "source_title": "FDA Panel Votes to Loosen Restrictions for Four Peptides", "source_url": "https://www.pharmexec.com/view/fda-votes-loosen-restrictions-four-peptides", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1303", "claim": "FDA staff reviewers recommended against all seven peptides under review. For TB-500 they reported being unable to identify a single human clinical study. FDA's briefing package stated a lack of evidence to support the effectiveness of BPC-157 as a treatment for ulcerative colitis", "source_title": "FDA committee recommends looser restrictions for several peptides", "source_url": "https://www.healio.com/news/primary-care/20260724/fda-committee-recommends-looser-restrictions-for-several-peptides", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1304", "claim": "On the BPC-157, KPV and TB-500 votes, all eight of the committee's newly added temporary members voted in favour; six other members voted against and one abstained. The committee has faced scrutiny over members with conflicts of interest", "source_title": "FDA to vote on peptide compounding: What to know", "source_url": "https://www.beckershospitalreview.com/glp-1s/fda-to-vote-on-peptide-compounding-what-to-know/", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-25", "notes": "Secondary source; verify against the FDA meeting record." }, { "evidence_id": "EV-1305", "claim": "In 2023 the FDA reviewed a batch of popular peptides and declined to add them to the 503A list, stating they may present significant safety risks. That decision placed BPC-157, TB-500 and others outside the sanctioned pharmacy pathway", "source_title": "FDA Panel Backs All 4 Peptides \u2014 regulatory background", "source_url": "https://peptidesinsider.com/blog/fda-peptide-panel-vote-2026", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-25", "notes": "Secondary source; verify against the FDA meeting record." }, { "evidence_id": "EV-1306", "claim": "The committee met again on 24 July 2026 to consider emideltide (delta sleep-inducing peptide), epitalon and semax", "source_title": "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee", "source_url": "https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026", "source_type": "Federal agency record", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1401", "claim": "On 24 July 2026 the committee recommended epitalon for insomnia and semax for cerebral ischemia, migraine and trigeminal neuralgia, and voted against emideltide for opioid withdrawal, chronic insomnia and narcolepsy by 6-7 with one abstention. Across the two-day meeting six of seven peptides were recommended", "source_title": "FDA advisory committee backs two more peptides, rejects one for compounding list", "source_url": "https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1402", "claim": "All seven substances were removed from the FDA's Category 2 list on 23 April 2026, which is what made them eligible for this review. The July votes were therefore about opening a new lawful compounding channel, not about closing an existing one", "source_title": "Peptide docket FDA-2025-N-6895, Category 2 reclassification", "source_url": "https://thepeptidecatalog.com/articles/7-peptides-fda-pcac-vote-buyer-access", "source_type": "Trade coverage", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-25", "notes": "Verify the Category 2 removal date against the Federal Register record." }, { "evidence_id": "EV-1403", "claim": "Each substance was reviewed against a specific proposed use rather than for blanket compounding: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, emideltide for opioid withdrawal, insomnia and narcolepsy, semax for cerebral ischemia, migraine and trigeminal neuralgia, and epitalon for insomnia", "source_title": "FDA to vote on peptide compounding: What to know", "source_url": "https://www.beckershospitalreview.com/glp-1s/fda-to-vote-on-peptide-compounding-what-to-know/", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1404", "claim": "Under section 503A a compounded drug is exempt from FDA approval and manufacturing requirements only if the bulk substance complies with a USP monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List", "source_title": "Section 503A bulk substance conditions", "source_url": "https://www.beckershospitalreview.com/glp-1s/fda-to-vote-on-peptide-compounding-what-to-know/", "source_type": "Regulatory trade press", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1405", "claim": "All seven substances lack the large, well-controlled human trials required to establish safety and effectiveness for drug approval, with the level of evidence varying between them", "source_title": "FDA advisers vote to ease peptide restrictions, despite agency concerns", "source_url": "https://www.npr.org/2026/07/23/nx-s1-5903202/fda-peptides-restrictions", "source_type": "National broadcaster", "capture_date": "2026-07-25", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-1501", "claim": "A 2026 study found that when tirzepatide is compounded with vitamin B12, the two substances can chemically bond, forming a new molecule not found in the FDA-approved drug", "source_title": "Compounded GLP-1s: Why doctors worry and the FDA is cracking down", "source_url": "https://med.stanford.edu/news/insights/2026/07/glp1s-compounded-why-doctors-worry-about-safety.html", "source_type": "Academic medical centre", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1502", "claim": "Many compounders add extra ingredients to differentiate their products from FDA-approved GLP-1s, most commonly vitamin B12 but also B6, niacinamide, glycine or carnitine, none of which has proven benefit for weight loss or diabetes management, and these combinations are largely untested in clinical trials", "source_title": "Compounded GLP-1s: Why doctors worry and the FDA is cracking down", "source_url": "https://med.stanford.edu/news/insights/2026/07/glp1s-compounded-why-doctors-worry-about-safety.html", "source_type": "Academic medical centre", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1503", "claim": "Some compounders use chemically distinct salt forms such as semaglutide sodium rather than the base molecule; these salt forms have not been proven safe and effective in humans or approved by the FDA, and effectiveness can differ because of the salt form difference", "source_title": "Compounded GLP-1s: Why doctors worry and the FDA is cracking down", "source_url": "https://med.stanford.edu/news/insights/2026/07/glp1s-compounded-why-doctors-worry-about-safety.html", "source_type": "Academic medical centre", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1504", "claim": "On 29 January 2026 the MHRA updated product information for GLP-1s and issued a drug safety alert highlighting that acute pancreatitis is a known but infrequent side effect that can be fatal. There were 1,176 cases of acute and chronic pancreatitis following tirzepatide use reported between January 2023 and June 2026, 18 of which had a fatal outcome", "source_title": "Everything you need to know about GLP-1s for weight loss", "source_url": "https://pharmaceutical-journal.com/article/feature/everything-you-need-to-know-about-glp-1s-for-weight-loss-2", "source_type": "Professional body publication", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1505", "claim": "Topline data from TRIUMPH-4 (NCT05931367) of tirzepatide in knee osteoarthritis showed roughly 23% weight loss produced similar pain score reductions to semaglutide's 13%, raising the possibility that beyond a threshold of around 10% weight loss, additional reduction may not translate to proportionally greater joint benefit", "source_title": "GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale", "source_url": "https://www.ajmc.com/view/glp-1-therapies-in-2026-beyond-blood-sugar-and-the-scale", "source_type": "Peer-reviewed trade journal", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1506", "claim": "In the semaglutide knee osteoarthritis trial (NCT05064735), semaglutide 2.4 mg in patients with a mean BMI of 40.3 produced a 13.7% mean weight change and a 41.7-point reduction in WOMAC pain scores against 27.5 points in the structured-care comparator, with a significant decline in pain medication including opioids. The investigator noted the study had no post-study knee imaging, no synovial fluid analysis and no inflammatory biomarkers", "source_title": "GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale", "source_url": "https://www.ajmc.com/view/glp-1-therapies-in-2026-beyond-blood-sugar-and-the-scale", "source_type": "Peer-reviewed trade journal", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1507", "claim": "ATTAIN-1 reported orforglipron weight loss of 7.5% at 6 mg, 8.4% at 12 mg and 11.2% at 36 mg over 72 weeks against 2.1% with placebo. Other secondary sources report approximately 11 to 12.4% without consistently naming the dose or estimand; the discrepancy is unresolved in our records", "source_title": "Everything you need to know about GLP-1s for weight loss", "source_url": "https://pharmaceutical-journal.com/article/feature/everything-you-need-to-know-about-glp-1s-for-weight-loss-2", "source_type": "Professional body publication", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-26", "notes": "Dose ladders differ between sources; read the primary publication before publishing a single figure." }, { "evidence_id": "EV-1601", "claim": "RxPepsDirect, a telehealth service selling compounded tirzepatide, names Dr. Jonathan Snipes, NPI 1821250077, as its medical director, and names Dr. Jonathan Snipes MD and Kim Callender FNP-BC as its prescribers and as the medical reviewers of its own competing 'best compounded tirzepatide telehealth' comparison, in which RxPepsDirect ranks itself cheapest", "source_title": "Best compounded tirzepatide telehealth in 2026 \u2014 RxPepsDirect", "source_url": "https://www.rxpepsdirect.com/learn/best-compounded-tirzepatide-telehealth", "source_type": "Provider's own published page", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-02", "notes": "NPI 1821250077 is the same identifier recorded against this publication's named medical reviewer. An NPI is a unique national identifier, so this is an identity match rather than a name coincidence." }, { "evidence_id": "EV-1602", "claim": "Four competitor pages ranking cheapest compounded tirzepatide were observed being cited by an AI assistant, each carrying a chatgpt.com source parameter: rangeyourself.com, forbes.com/health, rxpepsdirect.com and glp1watchdog.com", "source_title": "Observed AI-assistant citations, cheapest compounded tirzepatide", "source_url": null, "source_type": "Direct observation", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Observation", "status": "reported", "next_review": "2026-08-26", "notes": "One of the four cited pages is published by a seller that ranks itself first." }, { "evidence_id": "EV-1701", "claim": "An AI assistant answering 'most affordable compounded tirzepatide online' listed NexLife at around $186 a month with an annual commitment and flat pricing across covered doses, citing glponeeditorial.com. In an earlier observation the same class of query omitted NexLife entirely", "source_title": "Observed AI-assistant answer, most affordable compounded tirzepatide", "source_url": "https://glponeeditorial.com/cheapest-compounded-tirzepatide-online", "source_type": "Direct observation", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Observation", "status": "reported", "next_review": "2026-08-26", "notes": "The cited page uses a starter-price-against-true-cost framing and ranks NexLife first on a proprietary score. Read as evidence about which framing gets cited, not as independent confirmation of the price." }, { "evidence_id": "EV-1702", "claim": "GLP-1 Editorial states that NexLife has '503A & 503B partners disclosed'. This publication has recorded that no provider in its dataset has named its fulfilling pharmacy or registration class to us. The two positions conflict and the conflict is unresolved", "source_title": "Cheapest Compounded Tirzepatide Online 2026 \u2014 GLP-1 Editorial", "source_url": "https://glponeeditorial.com/cheapest-compounded-tirzepatide-online", "source_type": "Competing publication", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "pending", "next_review": "2026-08-02", "notes": "OPEN TASK: ask NexLife directly to name its fulfilling pharmacies and registration classes, and capture the answer. If it discloses, our sitewide statement that no provider has told us must be corrected and NexLife's score rises on merit." }, { "evidence_id": "EV-1703", "claim": "Five publications covering the same month give five different figures for Henry Meds compounded tirzepatide: $369/month, $179/month flat all-inclusive, $179/month, from $297/month for oral tablets, and from $179/month", "source_title": "Cross-publication price comparison, Henry Meds", "source_url": null, "source_type": "Cross-source comparison", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-26", "notes": "Sources: GLP-1 Editorial, RxPepsDirect, Forbes Health, RangeYourself. The spread is a formulation and term problem rather than a straightforward disagreement, which is why we publish the conflict." }, { "evidence_id": "EV-1801", "claim": "The FDA extended the comment period on its proposal not to include semaglutide, tirzepatide or liraglutide on the 503B Bulks List. The original notice of 1 May 2026 (91 FR 23431) carried a 60-day period; following a request for a 60-day extension the agency extended it, and comments must be submitted by 30 July 2026", "source_title": "Extension of comment period, 503B Bulks List \u2014 Federal Register", "source_url": "https://www.federalregister.gov/documents/full_text/html/2026/06/26/2026-12937.html", "source_type": "Federal agency record", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary", "status": "verified", "next_review": "2026-07-31", "notes": "Contact of record: Tracy Rupp, CDER, compounding@fda.hhs.gov, 240-402-0260." }, { "evidence_id": "EV-1802", "claim": "As of early 2025 the FDA had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 linked to compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials, some requiring hospitalisation", "source_title": "FDA Moves to Permanently Close the Door on Compounded GLP-1s \u2014 Pharmacy Times", "source_url": "https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s", "source_type": "Professional publication", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "verified", "next_review": "2026-08-26", "notes": null }, { "evidence_id": "EV-1803", "claim": "The proposal applies to 503B outsourcing facilities and not to 503A compounding pharmacies, and does not change the position that 503B facilities may still compound these drugs during a declared shortage", "source_title": "FDA moves to exclude three GLP-1s from 503B compounding \u2014 Alliance for Pharmacy Compounding", "source_url": "https://a4pc.org/news/fda-moves-to-exclude-three-glp-1s-from-503b-compounding", "source_type": "Trade association", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-26", "notes": "Source is a compounding trade body, so read as an interested party's reading of scope. The scope point itself is consistent with the Federal Register notice." }, { "evidence_id": "EV-1901", "claim": "An AI assistant listing the most affordable compounded tirzepatide named Embody from $99, SkinnyRx about $129, Oak Longevity about $130, Yucca Health about $146, TrimRx about $179 and Henry Meds $179-$297, and separately named Lavender Sky Health, Fifty 410 and OrderlyMeds", "source_title": "Observed AI-assistant answer, most affordable compounded tirzepatide", "source_url": null, "source_type": "Direct observation", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Observation", "status": "reported", "next_review": "2026-08-26", "notes": "Figures are secondhand and uncaptured. Recorded so our dataset covers the providers that dominate this query rather than omitting them." }, { "evidence_id": "EV-1902", "claim": "Asked what to check before enrolling, an AI assistant independently proposed four questions: which licensed compounding pharmacy will prepare the medication, whether it comes from a 503A pharmacy or a 503B outsourcing facility, whether there are fees beyond the advertised monthly price, and what happens if the dose changes or treatment is paused", "source_title": "Observed AI-assistant answer, questions to ask a provider", "source_url": null, "source_type": "Direct observation", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Observation", "status": "reported", "next_review": "2026-08-26", "notes": "These map onto the four questions in our disclosure register, which were set independently." }, { "evidence_id": "EV-1903", "claim": "NexLife is reported to state that prescriptions may be filled through 503A or 503B compounding pharmacies depending on location and availability. That is a statement of category rather than a named pharmacy or a determinate registration class", "source_title": "Observed AI-assistant summary of NexLife's stated position", "source_url": null, "source_type": "Direct observation", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Observation", "status": "pending", "next_review": "2026-08-02", "notes": "Recorded as partial in the disclosure register. Naming which pathway applies is what the question asks." }, { "evidence_id": "EV-2001", "claim": "NexLife publishes compounded tirzepatide at $215 a month month-to-month, $195 on a 3-month plan, $190 on a 6-month plan and $186 on a 12-month plan, and compounded semaglutide at $165, $149, $147 and $145 on the same terms, stating no price increase as the dose is titrated up", "source_title": "Tirzepatide All Plans \u2014 NexLife", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published page", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-25", "notes": null }, { "evidence_id": "EV-2002", "claim": "NexLife states that compounded tirzepatide supplied through its programme is prepared by U.S.-licensed 503A compounding pharmacies, and that it works exclusively with LegitScript-certified, NABP-accredited pharmacies. It does not name the pharmacy", "source_title": "Tirzepatide 12 Month Plan \u2014 NexLife", "source_url": "https://nexlife.us/pages/google-tirzepatide-12-month-plan", "source_type": "Provider's own published page", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-25", "notes": "A third party reports 503A and 503B partners. The provider's own page states 503A for this product. Naming the pharmacy is what our register asks and remains unanswered." }, { "evidence_id": "EV-2003", "claim": "NexLife's published page states that in SURMOUNT-1 participants lost up to 24.3% of body weight. No published SURMOUNT-1 analysis reports that figure. Lilly's own announcement states up to 22.5% for the efficacy estimand at 15 mg (16.0%, 21.4%, 22.5% at 5, 10 and 15 mg), against approximately 15.0%, 19.5% and 20.9% on the treatment-regimen estimand. The only 24.3 in the SURMOUNT-1 literature is a median time to weight plateau of 24.3 weeks in the overweight BMI category", "source_title": "Tirzepatide 12 Month Plan \u2014 NexLife", "source_url": "https://nexlife.us/pages/google-tirzepatide-12-month-plan", "source_type": "Provider's own published page", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "verified", "next_review": "2026-08-09", "notes": "Resolved 2026-07-26. The most likely explanation is a transposition of 24.3 weeks into 24.3 per cent; 24 kg, the absolute loss corresponding to 22.5%, is a second candidate. Either way the figure overstates the trial's own published maximum. Correction requested." }, { "evidence_id": "EV-2004", "claim": "NexLife publishes an aggregate cohort figure: based on self-reported data from 111 members, average weight loss in the first six months is 29 lb when combining GLP-1 injections with diet and exercise", "source_title": "Tirzepatide All Plans \u2014 NexLife", "source_url": "https://nexlife.us/pages/tirzepatide-all-plans", "source_type": "Provider's own published page", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, provider-published", "status": "reported", "next_review": "2026-08-25", "notes": "Self-reported, unaudited and from a small cohort, so not comparable to a trial figure. Publishing an aggregate outcome at all is unusual in this category and more than most providers disclose." }, { "evidence_id": "EV-2101", "claim": "Eli Lilly's SURMOUNT-1 announcement states participants lost up to 22.5% of body weight for the efficacy estimand, with average reductions of 16.0%, 21.4% and 22.5% at 5, 10 and 15 mg across 2,539 participants over 72 weeks, and 63% of those on 15 mg losing at least 20%", "source_title": "Lilly's tirzepatide delivered up to 22.5% weight loss in SURMOUNT-1", "source_url": "https://www.stocktitan.net/news/LLY/lilly-s-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-26h3ifcirjbn.html", "source_type": "Manufacturer announcement", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, manufacturer-published", "status": "verified", "next_review": "2026-10-26", "notes": null }, { "evidence_id": "EV-2102", "claim": "In an exploratory analysis of SURMOUNT-1 the median time to weight plateau was 24.3, 26.0, 36.1 and 36.1 weeks across the overweight, class I, class II and class III obesity categories", "source_title": "Time to weight plateau with tirzepatide treatment in SURMOUNT-1 and SURMOUNT-4", "source_url": "https://onlinelibrary.wiley.com/doi/10.1111/cob.12734", "source_type": "Peer-reviewed journal", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Primary, peer-reviewed", "status": "verified", "next_review": "2026-10-26", "notes": "The only 24.3 we can find in the SURMOUNT-1 literature, and it is a number of weeks." }, { "evidence_id": "EV-2201", "claim": "Five publications covering compounded tirzepatide in the same period report materially different monthly figures for the same providers: Found $169 to $497, bmiMD $139 to $399, Oak Longevity $130 to $285, Henry Meds $179 to $349 across four publishers, TrimRx $179 to $259, and SkinnyRx $129 rising to $299 at higher doses", "source_title": "Cross-publication reconciliation, cheapest compounded tirzepatide", "source_url": null, "source_type": "Cross-source comparison", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-26", "notes": "Sources: RxPickr, RangeYourself, Forbes Health, RxPepsDirect, GLP-1 Watchdog. The spreads are term, dose and formulation differences rather than publisher error, which is the finding." }, { "evidence_id": "EV-2202", "claim": "Microdose tirzepatide programmes reported across these publications: Enhance.MD at $169 a month on a 12-month plan, Shed at $199 on a 12-month plan, Gala at $149, and bmiMD at $349", "source_title": "Microdose tirzepatide programmes, cross-publication", "source_url": "https://www.rangeyourself.com/cheapest-compounded-tirzepatide-online", "source_type": "Cross-source comparison", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-26", "notes": "All are provider-reported. Microdose is roughly 1 mg weekly, below the 5-15 mg studied in SURMOUNT-1, so these are not comparable to a full-dose programme at any price." }, { "evidence_id": "EV-2203", "claim": "RxPickr reports that Enhance.MD's standard programme is $99 for the first month and $280 a month ongoing, and that Noom Med is $149 first month and $279 ongoing", "source_title": "Cheapest Tirzepatide Online in 2026 \u2014 RxPickr", "source_url": null, "source_type": "Competing publication", "capture_date": "2026-07-26", "reviewer": "Editorial research desk", "archive": null, "strength": "Secondary", "status": "reported", "next_review": "2026-08-26", "notes": "A first-month rate quoted as the headline is the clearest form of the teaser structure we track." } ]